Manuel Sousa, José <br/><br/>
Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.  [electronic resource] 

 -  PloS one  2019 
 - e0225061 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0225061  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>2-Naphthylamine<br/>Anilides--adverse effects<br/>Antiviral Agents--adverse effects<br/>Carbamates--adverse effects<br/>Cyclopropanes<br/>Drug Therapy, Combination<br/>Female<br/>Follow-Up Studies<br/>HIV Infections--drug therapy<br/>HIV-1--genetics<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Lactams, Macrocyclic<br/>Logistic Models<br/>Macrocyclic Compounds--adverse effects<br/>Male<br/>Middle Aged<br/>Multivariate Analysis<br/>Proline--analogs & derivatives<br/>Ribavirin--adverse effects<br/>Spain<br/>Sulfonamides--adverse effects<br/>Sustained Virologic Response<br/>Treatment Outcome<br/>Uracil--adverse effects<br/>Valine